BIO-Europe Spring® 2016: Synthetic Biologics CEO outlines development plans for lead assets

April 19, 2016
Synthetic Biologics CEO Jeffrey Riley outlines to Pharma Intelligence Senior Editor Sten Stovall how the clinical stage developer of therapeutics to protect the gut microbiome while targeting pathogen-specific diseases plans to advance its pipeline, which currently contains two lead candidates in Phase II. The most advanced, SYN-004, is designed to protect the gut microbiome from the effects of certain commonly used intravenous beta-lactam antibiotics for the prevention of C. difficile infection and antibiotic-associated diarrhea (AAD). SYN-010 aims to reduce the impact of methane producing organisms in the gut.
Previous Video
BIO-Europe Spring® 2016: Lucentis biosimilar to be sold to emerging markets by Xbrane Biopharma
BIO-Europe Spring® 2016: Lucentis biosimilar to be sold to emerging markets by Xbrane Biopharma

The CEO of Stockholm-based Xbrane Biopharma Martin Åmark tells Pharma Intelligence Senior Editor Sten Stova...

Next Video
BIO-Europe Spring® 2016: Environment in 2016: Reverse engineering the ecosystem
BIO-Europe Spring® 2016: Environment in 2016: Reverse engineering the ecosystem